NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 16.6% and is now trading at $38.36. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.21. The biotechnology company earned $17.60 million during the quarter, compared to the consensus estimate of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The business's revenue was up 1855.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.89) EPS. View Regenxbio's earnings history.

6 equities research analysts have issued 1-year price targets for Regenxbio's stock. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's stock price to reach $68.33 in the next year. This suggests a possible upside of 78.1% from the stock's current price. View analysts' price targets for Regenxbio.

Press coverage about RGNX stock has been trending neutral on Friday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Novavax (NVAX), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Immunovant (IMVT) and Alector (ALEC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.36.

Regenxbio has a market capitalization of $1.43 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]